Pfizer dumps a fading pipeline star, giving up on its PCSK9 drug bococizumab
You can scratch any hopes you might have had that Pfizer could mount a come-from-behind win and seize the lead from Amgen and Sanofi/Regeneron in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
